Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 0.72 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400226 | 0.99 | HRH3 (0.71) | HRH3HRH1KCNH2 | |
| SCHEMBL4398407 | 0.99 | HRH3 (0.71) | HRH3HRH1KCNH2 | |
| SCHEMBL4398655 | 0.91 | HRH3 (0.73) | HRH3HRH1KCNH2 | |
| SCHEMBL4400109 | 0.89 | HRH3 (0.58) | HRH3HRH1 | |
| SCHEMBL4392910 | 0.86 | HRH3 (0.71) | HRH3 | |
| SCHEMBL4398179 | 0.86 | HRH3 (0.60) | HRH3KCNH2 | |
| SCHEMBL4399987 | 0.86 | HRH3 (0.72) | HRH3HRH1 | |
| SCHEMBL4391275 | 0.85 | HRH3 (0.64) | HRH3HRH1 | |
| SCHEMBL4400291 | 0.85 | HRH3 (0.64) | HRH3HRH1 | |
| SCHEMBL4393279 | 0.85 | HRH3 (0.73) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | claimed |
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | disclosed |
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | disclosed |
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | disclosed |
| EP-1833796-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006061193-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, INMT, INA | HRH3 2097/4885HRH1 2957/4885KCNH2 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.